LLY - Lilly ALX Oncology collaborate in gastric or gastroesophageal cancer

ALX Oncology (ALXO) inks clinical trial collaboration and supply agreement with Eli Lilly (LLY) to evaluate the combination of ALX148, a next generation CD47 blocker, and Cyramza (ramucirumab), Lilly’s anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer. Under the terms of the agreement, ALX Oncology will conduct a Phase 2/3 study to evaluate the efficacy of ALX148 in combination with ramucirumab, trastuzumab, and paclitaxel for the treatment of patients whose tumors have progressed following treatment with HER2-targeted therapy and chemotherapy.Lilly will supply ramucirumab for this trial.Financial details are not disclosed.

For further details see:

Lilly, ALX Oncology collaborate in gastric or gastroesophageal cancer